Ibex earns FDA Clearance for Cancer Detection Tool

Building a startup is never easy. Building one in healthcare AI—where the stakes are literally life and death—takes another level of resilience, scientific rigor, and long-term vision. That’s why today’s news from Ibex Medical Analytics is so exciting: the company has secured FDA clearance for its Ibex Prostate Detect, a prostate cancer detection tool.

Pathologists are the unsung heroes of cancer care, but they’re under immense pressure: rising case volumes, growing complexity, and a global shortage of trained experts. Ibex Prostate Detect leverages complex AI algorithms to identify and grade cancers that might otherwise be missed. In clinical validation, the system identified 13% of cancers that were initially diagnosed as benign cases that could have led to missed treatment and worse outcomes. It also achieved an impressive 99.6% positive predictive value, proving its reliability in assisting pathologists with accurate, timely diagnoses.

This is a huge milestone and builds on momentum for the company including:
✅Secured CE-IVDR approval for its breast and gastric cancer AI solutions, reinforcing its global regulatory leadership
✅Raised a $55M growth round, fueling continued expansion and R&D
✅ Expansion into the U.S. market  and establishing strategic partnerships with several major health systems

Each of these moments has brought the company closer to its mission: ensuring that every patient gets an accurate, timely diagnosis—a mission that becomes even more critical as cancer incidence continues to rise worldwide. Prostate cancer alone affects 1 in 8 men, with cases projected to double by 2040. AI won’t replace pathologists, but it will empower them to catch what might otherwise be missed, making care more precise and effective.

Having worked with Yossi Mossel, Chaim Linhart, and the Ibex team as an investor at DTC, I’ve seen firsthand the dedication and resilience it takes to build in this space. Healthcare startups don’t just move fast and break things—they move carefully, validate relentlessly, and prove clinical impact at every step. Ibex is doing exactly that.

This FDA clearance is a regulatory win for Ibex. And it’s also a sign that AI-driven cancer detection is ready for mainstream adoption. That’s something worth celebrating.

‍